Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT A WOLFF and MICHAEL JAMES OVERMAN.
ROBERT A WOLFF
Connection Strength
6.724
MICHAEL JAMES OVERMAN
  1. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol. 2010 May; 49(4):474-9.
    View in: PubMed
    Score: 0.363
  2. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
    View in: PubMed
    Score: 0.332
  3. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45.
    View in: PubMed
    Score: 0.326
  4. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
    View in: PubMed
    Score: 0.323
  5. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
    View in: PubMed
    Score: 0.212
  6. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open. 2021 06; 6(3):100132.
    View in: PubMed
    Score: 0.194
  7. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 2020 11; 5(6):e000960.
    View in: PubMed
    Score: 0.188
  8. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2019 03 01; 30(3):495.
    View in: PubMed
    Score: 0.167
  9. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386.
    View in: PubMed
    Score: 0.165
  10. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018 01 01; 29(1):139-144.
    View in: PubMed
    Score: 0.154
  11. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
    View in: PubMed
    Score: 0.154
  12. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457.
    View in: PubMed
    Score: 0.150
  13. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.
    View in: PubMed
    Score: 0.148
  14. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017.
    View in: PubMed
    Score: 0.143
  15. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668.
    View in: PubMed
    Score: 0.140
  16. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074.
    View in: PubMed
    Score: 0.136
  17. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb; 5(2):239-47.
    View in: PubMed
    Score: 0.134
  18. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
    View in: PubMed
    Score: 0.115
  19. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53.
    View in: PubMed
    Score: 0.112
  20. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012 May; 19(5):1439-45.
    View in: PubMed
    Score: 0.102
  21. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658.
    View in: PubMed
    Score: 0.098
  22. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2010 Dec 01; 116(23):5374-82.
    View in: PubMed
    Score: 0.093
  23. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
    View in: PubMed
    Score: 0.091
  24. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010 Jan 05; 102(1):144-50.
    View in: PubMed
    Score: 0.088
  25. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.081
  26. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
    View in: PubMed
    Score: 0.079
  27. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol. 2024 Nov 01; 10(11):1519-1529.
    View in: PubMed
    Score: 0.062
  28. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist. 2024 Jul 16.
    View in: PubMed
    Score: 0.061
  29. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.060
  30. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel). 2024 Feb 09; 16(4).
    View in: PubMed
    Score: 0.059
  31. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024 Feb 03; 8(1):27.
    View in: PubMed
    Score: 0.059
  32. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
    View in: PubMed
    Score: 0.059
  33. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. 2023 Dec 11; 28(12):e1303-e1305.
    View in: PubMed
    Score: 0.058
  34. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517.
    View in: PubMed
    Score: 0.058
  35. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq. 2023 Aug 10.
    View in: PubMed
    Score: 0.057
  36. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma. medRxiv. 2023 Jul 13.
    View in: PubMed
    Score: 0.057
  37. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023 Feb 13; 7(1):16.
    View in: PubMed
    Score: 0.055
  38. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.055
  39. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. 2022 11 03; 27(11):952-957.
    View in: PubMed
    Score: 0.054
  40. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357.
    View in: PubMed
    Score: 0.054
  41. Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986.
    View in: PubMed
    Score: 0.053
  42. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3.
    View in: PubMed
    Score: 0.053
  43. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.053
  44. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656.
    View in: PubMed
    Score: 0.052
  45. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.051
  46. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274.
    View in: PubMed
    Score: 0.050
  47. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.049
  48. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.048
  49. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.048
  50. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.046
  51. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199.
    View in: PubMed
    Score: 0.046
  52. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
    View in: PubMed
    Score: 0.046
  53. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6.
    View in: PubMed
    Score: 0.046
  54. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.046
  55. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.044
  56. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.044
  57. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510.
    View in: PubMed
    Score: 0.043
  58. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
    View in: PubMed
    Score: 0.040
  59. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.039
  60. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.038
  61. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949.
    View in: PubMed
    Score: 0.038
  62. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279.
    View in: PubMed
    Score: 0.037
  63. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154.
    View in: PubMed
    Score: 0.036
  64. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345.
    View in: PubMed
    Score: 0.036
  65. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.036
  66. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.
    View in: PubMed
    Score: 0.036
  67. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.036
  68. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.035
  69. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.035
  70. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84.
    View in: PubMed
    Score: 0.032
  71. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.032
  72. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
    View in: PubMed
    Score: 0.031
  73. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
    View in: PubMed
    Score: 0.030
  74. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4):307-13.
    View in: PubMed
    Score: 0.030
  75. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26.
    View in: PubMed
    Score: 0.029
  76. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
    View in: PubMed
    Score: 0.029
  77. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
    View in: PubMed
    Score: 0.028
  78. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22.
    View in: PubMed
    Score: 0.022
  79. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
    View in: PubMed
    Score: 0.022
  80. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
    View in: PubMed
    Score: 0.022
  81. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
    View in: PubMed
    Score: 0.020
  82. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.
    View in: PubMed
    Score: 0.020
  83. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.